Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology

Implementing Telemedicine Intervention in Neonatal Intensive Care Units: Augmented Teleconsultation and Real-Time Monitoring Experience

Background

Increasing intensivist shortages and demand, coupled with the escalating bed occupancy rate due to increased demand for neonatal intensive care units (NICUs), have created enthusiasm for tele-critical care (TCC) in the form of teleconsultations. Consequently, this study aimed to describe the role of TCC intervention in enhancing NICU capacity to manage discharge, bed occupancy, and neonatal mortality rates.

Methods

This was an uncontrolled, retrospective, interventional descriptive study conducted over 22 months from January 2021 to October 2022 in a public hospital in Najran, Saudi Arabia. We employed the scheduled care model of TCC, in which an intensivist provides daily rounds, overnight calls, and critical care consultations upon request. Real-time outcomes, including mortality, discharge, and bed occupancy rates, were monitored in real-time by the National Healthcare Command Center.

Results

Implementing the TCC program was associated with an overall reduction of 10.7% in the neonatal mortality rate from 10.3 to 9.2 deaths per 1000 live births. The discharge rate increased from 0% in the early months of the TCC application to 34.12% after 4 months of application despite the increased bed occupancy rate. The study revealed no statistically significant difference in mortality rates between the means of pre- and post-TCC (M = 9.74, SD = 4.32), (M = 10.28, SD = 7.99) respectively, p = 0.856 with a 95% confidence interval of -5.58 to 6.66.

Conclusions

TCC in virtual scheduled consultations with a real-time dashboard was proven successful in controlling neonatal mortality and discharge rates. Further studies are required with extended follow-up periods and involving parameters such as the acceptance of physicians, long-term effects beyond the NICU, and the impact of TCC on logistics and resources.

Influence of the COVID-19 pandemic on patients receiving oral anticoagulants for the treatment of non-valvular atrial fibrillation

Background

Frequent monitoring of patients declined during the COVID-19 pandemic, harming patients with chronic diseases who critically needed correct monitoring. We evaluated the impact of the COVID-19 pandemic in patients with non-valvular atrial fibrillation (NVAF) receiving treatment with vitamin K antagonists (VKA) or non-vitamin K antagonist oral anticoagulants (NOAC) in clinical practice in Spain.

Methods

This observational, retrospective study analyzed prevalent patients treated with NOAC/VKA on 14/03/2019 (pre-COVID-19 period) and 14/03/2020 (COVID-19 period), who were followed up to 12 months. The study also considered incident patients who started treatment with NOAC/VKA between 15/03/2019 and 13/03/2020 (pre-COVID-19 period) and from 15/03/2020 to 13/03/2021 (COVID-19 period). Demographic characteristics, comorbidities, effectiveness, treatment patterns, and healthcare resource utilization were considered.

Results

Prevalent patients amounted to 12,336 and 13,342 patients, whereas 1,612 and 1,602 incident patients were included in the pre-COVID-19 and COVID-19 periods, respectively. Prevalent patients treated with VKA had more strokes, thromboembolism, and major bleeding compared to those receiving NOAC, particularly during the COVID-19 period. NOAC patients had a 12 % lower risk of death than those on treatment with VKA (Hazard ratio = 0.88 [95 % CI: 0.81 - 0.95], p = 0.033). In addition, VKA patients were less persistent after 12 months than NOAC patients (pre-COVID-19 period: 52.1 % vs. 78.9 %, p < 0.001; COVID-19 period: 49.2 % vs. 80.3 %, p < 0.001), and required more healthcare visits and hospitalizations than those on treatment with NOAC.

Conclusion

Compared to VKA, NOAC seems to have reduced the incidence of severe events and the use of healthcare resources for NVAF, particularly during the pandemic.

A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study

Background

During the COVID-19 pandemic, guideline documents on the management of anticoagulation were rapidly published. However, these documents did not follow a structured methodology, and significant differences existed between the guidelines. The aim of this expert consensus was to provide recommendations on the clinical management of oral anticoagulation in patients in the context of the COVID-19 pandemic.

Methods

A two-round Delphi study was conducted using an online survey. In the first round, panellists expressed their level of agreement with the items on a 9-point Likert scale. Items were selected if they received approval from ≥66.6% of panellists and if they were agreed by the scientific committee. In the second round, panellists revaluated those items that did not meet consensus in the first round.

Results

A total of 147 panellists completed the first round, and 144 of them completed the second round. Consensus was reached on 161 items included in five dimensions. These dimensions addressed: (I) management of anticoagulation in patients with atrial fibrillation (AF) without mechanical valves or moderate/severe mitral stenosis during COVID-19 infection; (II) thromboprophylaxis in patients hospitalised for COVID-19; (III) management of anticoagulation at hospital discharge/after COVID-19; (IV) anticoagulation monitoring in the COVID-19 pandemic setting; and (V) role of telemedicine in the management and follow-up of patients with AF in the COVID-19 pandemic setting.

Conclusions

These areas of collective agreement could specially guide clinicians in making decisions regarding anticoagulation in patients with COVID-19 during hospitalisation and at discharge, where results from clinical trials are still limited and, in some cases, conflicting.

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

Heart failure (HF) is a progressive condition with periods of apparent stability and repeated worsening HF events. Over time, unless optimization of HF treatment, worsening HF events become more frequent and patients enter into a cycle of recurrent events with high morbidity and mortality. In patients with HF there is an activation of deleterious neurohormonal pathways, such as the renin angiotensin aldosterone system and the sympathetic system, and an inhibition of protective pathways, including natriuretic peptides and guanylate cyclase. Therefore, HF burden can be reduced only through a holistic approach that targets all neurohormonal systems. In this context, vericiguat may play a key role, as it is the only HF drug that activates the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate system. On the other hand, it has been described relevant disparities in the management of HF population. Consequently, it is necessary to homogenize the management of these patients, through an integrated patient-care pathway that should be adapted at the local level. In this context, the development of new technologies (ie, video call, specific platforms, remote control devices, etc.) may be very helpful. In this manuscript, a multidisciplinary group of experts analyzed the current evidence and shared their own experience to provide some recommendations about the therapeutic optimization of patients with recent worsening HF, with a particular focus on vericiguat, and also about how the integrated patient-care pathway should be performed.

Cardiovascular disease and COVID-19, a deadly combination: A review about direct and indirect impact of a pandemic

Coronavirus disease 2019 (COVID-19) is known to present with respiratory symptoms, which can lead to severe pneumonia and respiratory failure. However, it can have multisystem complications such as cardiovascular manifestations. The cardiovascular manifestations reported comprise myocarditis, cardiogenic shock, arrhythmias, pulmonary embolism, deep vein embolism, acute heart failure, and myocardial infarction. There is also an indirect impact of the pandemic on the management of cardiovascular care that has been shown clearly in multiple publications. In this review, we summarize the deadly relation of COVID-19 with cardiovascular events and the wider impact on several cardiovascular care areas by the pandemic situation.

Cardiac Outpatient Care in a Digital Age: Remote Cardiology Clinic Visits in the Era of COVID-19

Purpose of Review

The worldwide pandemic caused by the novel coronavirus disease transformed healthcare in many ways. The impact of the pandemic was also noted in outpatient settings with various clinics adopting telehealth as the new normal. The goal of this paper is to investigate how the pandemic impacted the outpatient cardiology setting, specifically regarding the use of telehealth, and can the lessons learned from the adoption of telehealth in the backdrop of COVID-19 be applied to facilitate the wider and routine use of telemedicine in the outpatient cardiology clinic.

Recent Findings

Several studies have been conducted showcasing COVID-19’s impact on the telehealth field of cardiology. Studies showed advantages for patients. Among these advantages are reduction in wait and travel time, easier medication reconciliation, and convenience. They also showed a general comfortability with the transition to telehealth among cardiologists. Furthermore, the adoption of telehealth in the outpatient cardiology setting, specifically with respect to the management of common cardiac conditions of congestive heart failure, atrial fibrillation, and ischemic heart disease, revealed the potential of telemedicine to be used to adequately address these conditions. The transition to telehealth was not without its challenges, such as lack of a physical exam, barriers with certain patient populations to adopting the technology, and changes were noted in frequencies of medication ordering and cardiology-specific laboratory and diagnostic imaging.

Summary

This transition to telehealth during the pandemic allowed for various studies to be conducted on how telehealth impacted the field of cardiology in the outpatient setting. While patient and practitioner advantages were revealed when compared to traditional outpatient cardiology visits, barriers to the adoption of the technology among specific patient populations were noted as were changes in practice among cardiologists. The use of telemedicine to adequately address common cardiac conditions was also shown. Further investigation into understanding the barriers of specific patient populations and overcoming these barriers, understanding the reason for the changes in practice of cardiologists with the use telemedicine, and investigating the use and incorporation of existing technology such as smart watches and patient portals or apps to make the transition to telehealth not only simpler, but to also optimize the cardiologist management of common cardiac conditions, have the potential to lead to the wider and routine use of telemedicine in the outpatient cardiology clinic.

[Telemedicine, ethics, and law in times of COVID-19. A look towards the future]

The health emergency in Spain caused by COVID-19 was of such a magnitude that on March 14, 2020, a state of alarm was declared that lasted for more than three months. This ongoing pandemic has affected a vast number of people. Among the measures taken to reduce the risk of contagion, visits to health centers have been reduced and virtual consultations have increased. Once the pandemic ends, it will be necessary to consider whether telemedicine should be limited to periods of health crises or whether it could become a new way of practicing medicine. Telemedicine lacks specific regulations and has loopholes that leave physicians with a considerable degree of insecurity. This article analyzes the limits, precautions, and legal standards of the use of telemedicine.

An evaluation of cardiology virtual care during the COVID-19 pandemic

A survey evaluation was conducted in the division of cardiology at a tertiary care academic centre to assess barriers, facilitators, acceptability, and feasibility of virtual care during the COVID-19 pandemic. Survey responses from 26 health care providers, 45 patients, and 2 caregivers showed that virtual visits (primarily by telephone) were feasible and generally acceptable to most respondents. Key opportunities for improvement included availability of easy-to-use video platforms, space and equipment in clinics, provision of information to patients before visits, and appropriate selection of patients for virtual visits. Results will inform optimization of virtual care during this pandemic and beyond.

Tele-Rheumatology During the COVID-19 Pandemic

INTRODUCTION

During the COVID-19 pandemic strategies to prevent transmission of the viral infection obliged our hospital to promote virtual consultations.

OBJETIVE

The objective of this study is to describe the results obtained with the previous strategy of transferring activity to teleconsultation during the period of maximum impact of the pandemic.

MATERIAL AND METHODS

Between 16/03 and 10/05/2020 all successive consultations in our unit were performed in virtual rheumatology teleconference (RTC) format. The socio-demographic, geo-functional and clinical characteristics of all patients were collected; a numeric verbal scale (NVS) (where 0=very dissatisfied to 10=fully satisfied) was applied to assess the degree of satisfaction of the doctor/patient with the RTC.

RESULTS

469 TC were included. Most patients seen by RTC were women, mean age: 60,83 years. Only 16% had university education. The mean distance travelled for face-to face consultation is 33 Km with a mean total time of 2hours. Most individuals were diagnosed with osteoarthritis/soft tissue rheumatic diseases and/or osteoporosis; 21% had rheumatoid arthritis. The mean length of the TC was 9.64minutes. We find more patient satisfaction with the TC when their level of education is higher (OR=4.12); doctor satisfaction was higher when the individual was better able to manage the Internet (OR=3.01).

CONCLUSION

It is possible to transfer rheumatological care activity to TC with a considerable degree of satisfaction for both the patient and the doctor.